Poximune C

This page contains information on Poximune C for veterinary use.
The information provided typically includes the following:
  • Poximune C Indications
  • Warnings and cautions for Poximune C
  • Direction and dosage information for Poximune C

Poximune C

This treatment applies to the following species:
Manufacturer: Ceva Biomune

Canary Pox Vaccine, Modified Live Virus

U.S. Vet. Lic. No.: 368

Contents: POXIMUNE® C is a modified live virus vaccine that when administered to susceptible canaries confers immunity to canary pox disease. The vaccine is supplied in lyophilized (freeze-dried) form and is supplied with diluent and a single needle vaccinator for the wing web application.

Poximune C Indications

POXIMUNE® C is indicated for the immunization of canaries against canary pox virus infection. All susceptible birds on the same premises should be vaccinated at the same time. Young birds may be vaccinated at weaning age. Booster vaccinations are recommended every 6 to 12 months (depending on the disease risk) and four weeks prior to laying or vector season. Vaccination in the face of a disease outbreak is also indicated and has been demonstrated to control the outbreak and stop mortality in those birds not yet showing clinical symptoms.

Dosage and Administration

Immediately prior to administration the desiccated vaccine is dissolved with the diluent supplied. The single needle vaccinator is dipped into the mixed vaccine to completely fill the groove of the needle with the proper vaccine dose. Vaccination is accomplished by piercing the needle through the underneath surface of the wing-web which should be devoid of feathers. The administration should be a slow, steady motion (not a quick poke) to ensure release of the entire vaccine dose from the needle groove onto the epithelial tissue. See package insert for complete information.

Post-Vaccination: Following wing-web vaccination, typical cutaneous pox lesions should develop locally (at the site of inoculation) which correlate with immunity or “take” of the vaccine. At about 7-10 days post vaccination, the wing-web should be examined for a satisfactory “take” reaction characterized by a focal point of swelling, inflammation or scab formation at the site of inoculation. Revaccination is recommended if a “take” reaction is not evident. Although immunity begins to develop immediately following vaccination, three (3) to four (4) weeks are required to establish maximum immunity.

Precaution(s): Store in the dark at 35°-45°F.

Use the entire contents when first opened. Burn the container and all unused contents.

Caution(s): Vaccinate healthy birds only. Do not rehydrate the vaccine until ready for use because the rehydrated vaccine virus is rapidly perishable.

For veterinary use only.

Warning(s): Do not vaccinate within four (4) weeks of onset of egg production or during egg production.

Discussion: The vaccine is used to protect canaries against canary pox disease, a highly infectious and fatal disease in canaries commonly spread by mosquitoes or direct contact between birds. Clinical expression of the disease varies from an acute respiratory form to a chronic form with skin lesions around the eyes, beak or feet. Mortality rates are devastating and can reach 100%.

Presentation: 1 x 10 dose vials of vaccine, 1 x 10 dose vials of diluent, wing-web vaccinators;
10 x 10 dose vials of vaccine, 10 x 10 dose vials of diluent, wing-web vaccinators.

NAC No.: 11290253

CEVA BIOMUNE
8906 ROSEHILL ROAD, LENEXA, KS, 66215
Telephone:   913-894-0230
Fax:   913-894-0236
Website:   www.ceva-us.com
Every effort has been made to ensure the accuracy of the Poximune C information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-09-05

(web4)